Topiramate for pediatric migraine prevention

Area of Science:

• Neurology
• Pediatrics

Background:

• Adolescent migraine headaches frequently interfere with daily activities, prompting interest in prophylactic treatments.
• Topiramate is approved for migraine prevention in adults by Health Canada and the US FDA, and for adolescents (12-17 years) by the US FDA.

Purpose of the Study:

• To evaluate the effectiveness and safety of topiramate as a prophylactic therapy for adolescent migraine headaches.

Main Methods:

• Review of existing studies on topiramate for adolescent migraine prophylaxis.
• Consideration of a recent large multicentre, randomized placebo-controlled trial that was stopped early.

Main Results:

• While some smaller studies suggest effectiveness, a large recent trial indicated no significant benefit of topiramate over placebo.
• Adverse effects associated with topiramate are typically mild and tend to resolve over time.

Conclusions:

• Topiramate is an option for adolescent migraine prophylaxis, with a recommended dosage of 2 mg/kg/day (max 100 mg/day).
• The evidence supporting its efficacy in adolescents is not robust, despite regulatory approval in some regions.